Recent Company News

• 04:04 PM ET Jun 18, 2025
  

  Galapagos presents new data from cohort 3 of ATALANTA-1 for GLPG5101 in relapsed/refractory indolent NHL patients at ICML 2025 (€24.50, 0.00)

• 04:07 PM ET Jun 12, 2025
  

  Galapagos to present new ATALANTA-1 CAR-T data at EHA 2025; highlights low toxicity and rapid, decentralized delivery of fresh, early-memory-enriched GLPG5101 in R/R NHL (€24.84, 0.00)

• 04:39 PM ET May 14, 2025
  

  Galapagos announces oral presentations at EHA and ICML 2025 (€23.70, 0.00)

• 05:06 PM ET May 13, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:52 AM ET May 13, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:56 AM ET May 13, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:56 AM ET May 13, 2025
  

  Galapagos upgraded to buy from neutral at Van Lanschot Kempen (€22.80, 0.00)

• 01:43 AM ET May 13, 2025
  

  Galapagos has decided to re-evaluate the previously proposed separation and will explore all strategic alternatives for its existing businesses. Announces CEO change. (€22.80, 0.00)

• 12:46 AM ET May 13, 2025
  

  Barclays transfers GLPG.NA, GMAB.DC

• 04:05 PM ET Apr 23, 2025
  

  Galapagos reports Q1 EPS cont ops (€2.35) vs year-ago €0.36 (€22.46, 0.00)